Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

(2018) Elizabeth A. Killion et al.   Science Translational Medicine

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

(2018) Piotr A. Mroz et al.   Molecular Metabolism

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

(2018) Tamer Coskun et al.   Molecular Metabolism

Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

(2017) Valérie Turcot et al.   NATURE GENETICS

Neuronal Rap1 Regulates Energy Balance, Glucose Homeostasis, and Leptin Actions

(2016) Kentaro Kaneko et al.   Cell Reports

Genetic studies of body mass index yield new insights for obesity biology

(2015) Adam E. Locke et al.   NATURE

TCF1 links GIPR signaling to the control of beta cell function and survival

(2015) Jonathan E Campbell et al.   NATURE MEDICINE

Chronic Reduction of GIP Secretion Alleviates Obesity and Insulin Resistance Under High-Fat Diet Conditions

(2014) D. Nasteska et al.   DIABETES

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide Receptor

(2013) Peter Ravn et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

(2013) B. Finan et al.   Science Translational Medicine

Is there a place for incretin therapies in obesity and prediabetes?

(2013) Jens Juul Holst et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Induction of Leptin Resistance by Activation of cAMP-Epac Signaling

(2011) Makoto Fukuda et al.   Cell Metabolism

Gipr Is Essential for Adrenocortical Steroidogenesis; However, Corticosterone Deficiency Does Not Mediate the Favorable Metabolic Phenotype of Gipr-/- Mice

(2011) H. E. Bates et al.   DIABETES

Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice

(2011) Emilie Faivre et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice

(2010) David W. Porter et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Molecular mechanisms underlying nutrient-stimulated incretin secretion

(2010) Helen E. Parker et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index

(2010) Elizabeth K Speliotes et al.   NATURE GENETICS

MyD88 Signaling in the CNS Is Required for Development of Fatty Acid-Induced Leptin Resistance and Diet-Induced Obesity

(2009) André Kleinridders et al.   Cell Metabolism

Endoplasmic Reticulum Stress Plays a Central Role in Development of Leptin Resistance

(2009) Lale Ozcan et al.   Cell Metabolism

Hypothalamic IKKβ/NF-κB and ER Stress Link Overnutrition to Energy Imbalance and Obesity

(2008) Xiaoqing Zhang et al.   CELL

Anatomical Profiling of G Protein-Coupled Receptor Expression

(2008) Jean B. Regard et al.   CELL

Enhanced Cortico-Amygdala Efficacy and Suppressed Fear in Absence of Rap1

(2008) B.-X. Pan et al.   JOURNAL OF NEUROSCIENCE